Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis

NCT03812029 is registered in ClinicalTrials.gov with Enyo Pharma as lead sponsor.

NCT NCT03812029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03812029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis
Lead sponsor
Enyo Pharma
Phase
Phase 2
Overall status
Completed
Start date
January 30, 2019
Completion date
July 6, 2021
Enrollment
120 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic steatohepatitis